Differential responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP) versus escitalopram in chronic major depression with and without early trauma

Dept. of Psychiaty, University of Freiburg0 个研究点开始时间: 2009年8月3日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•-Chronic MDD according to DSM-IV (modification: depressive symptomatology for at least one year), or recurrent MDE (third or greater episode with the immediately preceeding episode being no more than 2.5 years before the onset of the present episode)
•-age 18-65
•-score of at least 18 on the Montgomery-Asberg-Rating Scale for Depression (MADRS)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•-Acute risk for suicide
•-history of psychotic symptoms, bipolar disorder or dementia
•-Severe substance-related abuse or dependence disorder
•-Schizotypal, antisocial or borderline personality disorder
•-Serious medical condition
•-severe cognitive impairment
•-Absence of a response to previous adequate trial of the study medication/CBASP
•-Hypersensitivity to escitalopram
•-Treatment with a MAO-inhibitor within 1 week before the initiation of study treatment

发起方

Dept. of Psychiaty, University of Freiburg